OXiGENE to Present Preclinical Data Demonstrating Antitumor Activity of
ZYBRESTAT(R) in Pancreatic Neuroendocrine Tumor Model
Poster Presentation Slated for October 20, 2013 at AACR-NCI-EORTC Conference
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer, announced that data from a preclinical study of
ZYBRESTAT® (fosbretabulin tromethamine/combretastatin A-4 phosphate or CA4P)
demonstrating antitumor activity in a model of pancreatic neuroendocrine
tumors (PNETs) will be presented at the AACR-NCI-EORTC International
Conference on Molecular Targets and Cancer Therapeutics, being held in the
Hynes Convention Center, Boston, MA, October 19-23, 2013.
The data will be presented in a poster by ZiQiang Yuan, MD, Research Assistant
Professor, Department of Surgery, Albert Einstein College of Medicine. Steven
K. Libutti, MD, FACS, Professor of Surgery and Genetics, Albert Einstein
College of Medicine, and Montefiore Medical Center, is the senior author.
Details on the OXiGENE poster presentation are as follows:
Combretastatin A-4 Phosphate (CA4P) is effective for the
Title: treatment of functional pancreatic neuroendocrine tumors (PNETs)
in a transgenic mouse model
Authors: ZiQiang Yuan^1, Nikolas Zaphiros^1, Asha Adem^1, Norvilia
Etienne^1, Jai Balkissoon^2, Dai Chaplin^2, Steven K. Libutti^1
^1Albert Einstein College of Medicine, Bronx, NY; ^2OXiGENE,
South San Francisco, CA
Session ID/ Poster Session A; Angiogenesis and Antiangiogenesis Agents 1
Date & Time/ Sunday, October 20, 2013 12:30-3:00 pm, Exhibit Hall C-D
The abstract for this presentation can be viewed here:
OXiGENE is a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer. The Company's major focus is developing vascular
disrupting agents (VDAs) that selectively disrupt abnormal blood vessels
associated with solid tumor progression. The Company's lead clinical product,
ZYBRESTAT, is in development as a potential treatment for ovarian cancer and
anaplastic thyroid cancer (ATC). OXiGENE is dedicated to leveraging its
intellectual property and therapeutic development expertise to bring
life-extending and life-enhancing medicines to patients.
Safe Harbor Statement
This news release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Any or all of the
forward-looking statements in this press release, which include the timing of
advancement, outcomes, and regulatory guidance relative to our clinical
programs, achievement of our business and financing objectives, may turn out
to be wrong. Forward-looking statements can be affected by inaccurate
assumptions OXiGENE might make or by known or unknown risks and uncertainties,
including, but not limited to, the inherent risks of drug development and
regulatory review, and the availability of additional financing to continue
development of our programs.
Additional information concerning factors that could cause actual results to
materially differ from those in the forward-looking statements is contained in
OXiGENE's reports to the Securities and Exchange Commission, including
OXiGENE's reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no
obligation to publicly update forward-looking statements, whether because of
new information, future events or otherwise. Please refer to our Annual Report
on Form 10-K for the fiscal year ended December 31, 2012.
CONTACT: Investor and Media Contact:
Press spacebar to pause and continue. Press esc to stop.